{"Ticker": "LLY", "Company": "Eli Lilly & Co", "Sector": "Health Care", "Updated": "2022-09-22", "Rating": [{"Date": "2022-09-22", "Rating": "Upgrade", "Organization": "UBS", "Rating_Change": "Neutral to Buy", "Target_Change": "$335 to $363"}, {"Date": "2022-05-23", "Rating": "Initiated", "Organization": "SVB Leerink", "Rating_Change": "Outperform", "Target_Change": "$341"}, {"Date": "2022-04-06", "Rating": "Resumed", "Organization": "Morgan Stanley", "Rating_Change": "Overweight", "Target_Change": "$265 to $364"}, {"Date": "2022-03-10", "Rating": "Initiated", "Organization": "Daiwa Securities", "Rating_Change": "Outperform", "Target_Change": "$286"}, {"Date": "2022-01-21", "Rating": "Upgrade", "Organization": "DZ Bank", "Rating_Change": "Hold to Buy", "Target_Change": "$291"}, {"Date": "2022-01-03", "Rating": "Reiterated", "Organization": "Bernstein", "Rating_Change": "Mkt Perform", "Target_Change": "$250 to $300"}, {"Date": "2021-12-17", "Rating": "Initiated", "Organization": "Goldman", "Rating_Change": "Neutral", "Target_Change": "$236"}, {"Date": "2021-12-16", "Rating": "Reiterated", "Organization": "BofA Securities", "Rating_Change": "Buy", "Target_Change": "$285 to $300"}, {"Date": "2021-12-16", "Rating": "Reiterated", "Organization": "BMO Capital Markets", "Rating_Change": "Outperform", "Target_Change": "$311 to $320"}, {"Date": "2021-12-09", "Rating": "Resumed", "Organization": "Wells Fargo", "Rating_Change": "Equal Weight", "Target_Change": "$270"}, {"Date": "2021-11-19", "Rating": "Initiated", "Organization": "BMO Capital Markets", "Rating_Change": "Outperform", "Target_Change": "$311"}, {"Date": "2021-10-11", "Rating": "Upgrade", "Organization": "Berenberg", "Rating_Change": "Hold to Buy", "Target_Change": "$240 to $270"}, {"Date": "2021-09-29", "Rating": "Upgrade", "Organization": "Citigroup", "Rating_Change": "Neutral to Buy", "Target_Change": "$210 to $265"}, {"Date": "2021-08-05", "Rating": "Upgrade", "Organization": "DZ Bank", "Rating_Change": "Hold to Buy", "Target_Change": "$288"}, {"Date": "2021-07-27", "Rating": "Resumed", "Organization": "Truist", "Rating_Change": "Buy", "Target_Change": "$262"}, {"Date": "2021-06-24", "Rating": "Reiterated", "Organization": "Cantor Fitzgerald", "Rating_Change": "Overweight", "Target_Change": "$245 to $300"}, {"Date": "2021-01-19", "Rating": "Upgrade", "Organization": "Mizuho", "Rating_Change": "Neutral to Buy", "Target_Change": "$164 to $222"}, {"Date": "2020-12-10", "Rating": "Upgrade", "Organization": "Wolfe Research", "Rating_Change": "Peer Perform to Outperform", "Target_Change": "$147 to $183"}, {"Date": "2020-11-10", "Rating": "Resumed", "Organization": "Bernstein", "Rating_Change": "Mkt Perform", "Target_Change": "$150"}, {"Date": "2020-09-29", "Rating": "Initiated", "Organization": "Berenberg", "Rating_Change": "Hold", "Target_Change": "$144"}, {"Date": "2020-09-03", "Rating": "Upgrade", "Organization": "Morgan Stanley", "Rating_Change": "Equal-Weight to Overweight", "Target_Change": "$176"}, {"Date": "2020-06-16", "Rating": "Upgrade", "Organization": "Guggenheim", "Rating_Change": "Neutral to Buy", "Target_Change": ""}, {"Date": "2020-04-21", "Rating": "Downgrade", "Organization": "UBS", "Rating_Change": "Buy to Neutral", "Target_Change": "$157 to $158"}, {"Date": "2020-04-09", "Rating": "Downgrade", "Organization": "Morgan Stanley", "Rating_Change": "Overweight to Equal-Weight", "Target_Change": "$148"}, {"Date": "2020-02-06", "Rating": "Initiated", "Organization": "Mizuho", "Rating_Change": "Neutral", "Target_Change": ""}, {"Date": "2019-12-18", "Rating": "Upgrade", "Organization": "Morgan Stanley", "Rating_Change": "Equal-Weight to Overweight", "Target_Change": "$116 to $150"}]}